BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Aug 19, 2025 • 25min
William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron
He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall Street disappointment. He describes whether he agrees with the reactions or not, and how the totality of the obesity market is shaping up.
Aug 19, 2025 • 6min
Celebrating the 2025 Nucleate Alumni Summit
Nucleate leaders describe what Nucleate has done for their education and career, and what they are looking forward to at this year's global summit in Boston.
Aug 19, 2025 • 6min
After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires
Founder & CEO Ashoka Rejendra describes what the company offers, which is a not only a software package, but guidance on how to build and plan for the future. New entrepreneurs like those attending the Nucleate Summit are a natural prospect.
Aug 15, 2025 • 33min
Biotech Direct: MassBio CEO Kendalle Burlin O'Connell and Seaport Therapeutics Founder & CEO Daphne Zohar discuss NIH funding, recent developments at FDA, and improving the public's view of science
In this inaugural episode of Biotech Direct, BiotechTV's new show that will share the biotech industry's perspective on policy and regulatory news, Kendalle Burlin O'Connell and Daphne Zohar discuss the strategic importance of biotech to the United States, share their thoughts on new FDA initiatives, and brainstorm ways to raise public awareness of the importance of science.
Aug 15, 2025 • 21min
IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead
Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical significance. She shares her take on the totality of the data and discusses the road ahead, including a Q3 meeting the company will have with FDA.
Aug 13, 2025 • 24min
Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced programs. We discuss Stiff Person Syndrome, myasthenia gravis, MS and more.
Aug 13, 2025 • 8min
Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis
Co-Founder & CEO Jim Martineau walks us through the platform and describes the importance of being cell type specific. The company utilized a combination of AI and high-throughput chemistry in the wet lab.
Aug 13, 2025 • 20min
Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.
Aug 12, 2025 • 18min
IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year
Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets Darovasertib, a DLL3 ADC, MAT2A, and more.
Aug 12, 2025 • 19min
CytomX Therapeutics' years of work on its 'Probody' masking technology may be paying off at a time when there is growing focus on this approach - it presented key initial data on its EpCAM ADC in May
Chairman & CEO Sean McCarthy walks us through the science and describes what CytomX has learned about it over many years of working on masking. He discusses the recent EpCAM data, and highlights IFN-α2b and partnered programs.
